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Abstract
Aldehyde modified proteins have been associated with the development and/or progression of
alcoholic liver disease (ALD). These protein adducts are capable of initiating many immunological
responses that are harmful to the normal homeostasis of organism function. Previous studies have
shown that malondialdehyde (MDA) and acetaldehyde (AA) synergistically form a unique adduct
(MAA) with soluble proteins, which are capable of inducing cytokine release, T-cell proliferation,
and antibody production. The purpose of this study was to determine whether MAA-adduction can
elicit similar responses to cells using a well-defined tumor model. The mouse mastocytoma P815
tumor cell line was modified with MAA (P815-MAA) or left unmodified (P815) and 106 irradiated
cells were injected into DBA/2 mice once a week for 5 weeks. Serum was collected and tested for
antibody responses to P815 cells and the MAA epitope. Immunization of MAA-adducted P815 cells
into syngeneic DBA/2 mice induced a strong antibody response to the MAA epitope as determined
by ELISA on Alb and MAA-Alb (508 µg/ml and 1092 µg/ml, respectively). In addition, antibody to
unmodified P815 cells was detected by fluorescent technique. Mice immunized with P815 cells or
PBS showed little or no reactivity to the MAA epitope or P815 cells. Studies to assess IL-12
stimulation showed that peritoneal macrophages from P815 and PBS immunized animals produced
modest amounts of IL-12 (20 and 35 pg/ml) when stimulated with Alb or MAA-Alb. However,
macrophage from P815-MAA immunized mice responded to soluble MAA-adduct (142 pg/ml).
Finally, in tumor survival studies the mean survival was 14.25 days in PBS treated mice; 15.75 days
with P815 immunized mice and 18.25 days with P815-MAA immunized mice. Therefore, these data
strongly suggest that antibody responses are induced by P815 cells modified with MAA-adducts.
This may be a possible tool to begin looking at how alcohol metabolites potentially modify cells and/
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or cellular components making them recognizable to the immune system as foreign. It is thought that
these studies define a model system that will be useful in assessing antibody and potentially T cell
responses to cells that are modified by MAA.
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Introduction
A relationship between the immune system and alcoholic liver disease (ALD) has been reported
by many investigators (1–5). For example, there is an influx of immune cells found in liver
biopsies from alcoholic liver disease patients (1). Additionally, it has been shown that
substantial abnormalities occur in the humoral and cellular immune responses of patients with
liver disease associated with alcohol (6–10). While a number of different antigens have been
involved in these immune responses, no one epitope has been identified as the true mediator
of ALD.
Support for immune involvement in ALD is found in the detection of autoantibodies to various
antigens found in the serum of chronic ethanol-fed rats or patients with alcohol induced liver
injury. These autoantibodies include; CYP2E1 (11), alcohol dehydrogenase (ADH) (12)
hydroxyl ethyl free radicals (13), acetaldehyde/malondialdehyde modified protein adducts
(14–18), liver specific protein (LSP) (19,20), and liver membrane protein (LMA) (21,22), all
of which have been shown to play a role in alcohol liver disease. The ability of these chemicals
or proteins to modify cell surface membranes or cellular material under the right conditions
could help break tolerance and initiate an autoimmune response. Circulating autoantibodies
specific for liver proteins or antibodies to adducts on proteins could trigger antibody-dependent
cell medicated cytotoxcity, killing or severely damaging hepatocytes, and causing increased
inflammation and eventually liver failure. This has been demonstrated using hydroxyl ethyl
radical-CYP2E1 adducts on the surface of isolated hepatocytes exposed to ethanol in the
presence of normal human peripheral blood mononuclear cells (23–26). Clearly, the sustained
ingestion of alcohol in most people appears result in the development of an array of auto-
antibodies to cellular proteins potentially initiating a T-cytotoxic response to hepatocytes
(23,27,28).
The finding of circulating antibodies specific for alcohol metabolites indicates there maybe a
cellular component involved. A report by Terabayashi; et al. supports the concept that cytotoxic
T lymphocytes can be generated that recognize syngeneic cells modified with acetaldehyde
(28). In studies consistent with findings reported in this manuscript, malondialdehyde-
acetaldehyde modified proteins have been shown to elicit T-cell proliferative responses through
antigen processing and presentation by macrophages and dendritic cells (29). Therefore, if
these cellular proteins are available for aldehyde binding and the right conditions are met to
produce these adducts, the potential for modification of self proteins or cells exists. These self
protein adducts could potentially induce an autoimmune disease mediated by antibodies, CD4
+ T-cells, antigen presenting cells, and/or by antibody-dependent cell mediated cytotoxicity.
Current work in this laboratory has shown that the in vivo metabolism of alcohol generates the
reaction of malondialdehyde (MDA) and acetaldehyde (AA) to form a unique adduct, that has
been designated as MAA (18). These MAA-adducts have been shown to elicit antibody and
T-cell response in the absence of adjuvants (29,30). However, these studies have all utilized
soluble proteins and no data is available with regard to the immune response to MAA-modified
cells. Therefore, the demonstration that MAA-modified cells can induce T-cell responses
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would suggest a possible mechanism for alcohol-induced liver damage. Therefore, it was the
purpose of this study to determine if MAA-adduction of tumor cells can elicit an immune
response that may serve as a model system of MHC class I restricted immune response in ALD.
Materials and Methods
Mice
Syngeneic DBA/2 mice were obtained from the National Cancer Institute via an interagency
agreement with the Department of Veterans Affairs and maintained on water and laboratory
chow ad libitum. The mice were monitored and determined to be pathogen-free. All procedures
were approved by the animal subcommittee of the Omaha VA Medical Center (accredited by
American Association for the Accreditation of Laboratory Animal AAALAC) and were in
accordance with guidelines of the National Institutes of Health (1985).
Cell line
The DBA/2 P815 mastocytoma cell line was purchased from the American Type Culture
Collection (ATCC, Manassas, VA) and maintained in RPMI 1640 medium supplemented with
10% fetal calf, 25 mM HEPES, 2 mM L-glutamine, gentamycin (100 U/ml), and incubated at
37°C in the presences of 5% CO2.
Chemicals and Proteins
Bovine serum albumin (Alb) was purchased from Cal Biochem (La Jolla, CA). Acetaldehyde
(AA) was obtained from Aldrich Chemical Co. (Milwaukee, WI). Malondialdehyde (MDA)
was obtained as the sodium salt (MDA~Na) by treatment of tetramethoxypropane (Aldrich
Chemical Co.) with NaOH, according to the method of Kikugawa and Ido (31). Phytic acid
(PA), and diethylenetriaminepentaacetic acid (DTPA) were obtained from Sigma Chemical
Co. (St. Louis, MO).
Preparation and Labeling of Ligands and P815 Cells
Bovine serum albumin-MAA (MAA-Alb) was prepared by reacting 1.0 mM AA and 2.0 mM
MDA with 2 mg of bovine serum albumin (Alb) in 0.1 M phosphate buffer pH 7.2, containing
2 mM DTPA and 2mM PA at 37°C for 3 days, followed by dialysis against 3 changes of 0.1
M sodium phosphate buffer for 24 hours at 4°C (18). P815 cells were modified by adjusting
to 1 × 106 cells/ml and reacting with 1.0 mM AA and 1.0 mM MDA in 0.1 M phosphate buffer
pH 7.2 containing 2 mM DTPA and 2 mM PA and incubated for 3 days at 37°C. Cells were
checked for modification by the amount of fluorescent MAA adduct present (excitation 398
nm and emission 460 nm) using a Perkin-Elmer (Norwalk, CT) LS-5B spectrofluorometer as
previously described by Tuma et. al. (18).
Immunization of DBA/2 mice
Prior to injection P815 or P815 AA and MDA adducted (P815-MAA) cells at a concentration
of 1 × 106 cells/ml were irradiated with 2000 Rads to guarantee that tumor cells would not
proliferate and kill the animal prior to challenging with lethal cells. Mice were immunized intra
peritoneal once a week for 5 weeks with 1 × 106 P815, P815-MAA, or phosphate buffered
saline (PBS) control irradiated cells. At the end of 6 weeks the mice were bled and infused via
the tail vein with a lethal dose of P815 cells which had been passaged through the ascites of a
normal DBA/2 mouse.
Lethal Dose Survival Curve
In order to determine the appropriate amount of lethal P815 cells to inject into DBA/2 mice
that would elicit tumor growth, a dose response of varying concentrations of cells was done.
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To make the P815 cell line virulent, cells had to be injected into the peritoneal cavity of a DBA/
2 mouse and the ascites fluid drawn out after approximately a week of growth. These cells
were counted and doses ranging from 102 to 106 were injected into animals, which were
monitored for days of survival. A liner dose curve was generated and 105 cells were used as
this would give us killing at around 14–15 days.
Assay for detection of antibody to the MAA-adduct
Sera from mice injected with PBS, irradiated P815 cells, or irradiated P815-MAA adducted
cells were screened by a direct ELISA for the presence of the MAA epitope. For these
experiments, 96 well Immulon IV (Nunc, Fisher Scientific, St. Louis, MO) microtiter plates
were coated with 20 µg/well Alb or MAA-Alb in the presence of bicarbonate buffer (pH 9.6)
as previously described (32). After an overnight incubation at 37°C, the plates were washed
three times with phosphate buffer saline containing 0.05% Tween 20 (PBST), the serum added
at a 1:50 dilution, and incubated at 37°C for 45 minutes. Plates were washed in PBST and a
secondary antibody (alkaline phosphatase rabbit anti-mouse IgG (H&L); Zymed Laboratories,
San Francisco, CA), was added and incubated at 37°C for 45 minutes. Previous work has
demonstrated that antibodies to MAA-modified proteins are IgG, therefore no other isotypes
were assayed (30). The plates were then washed and the substrate p-nitrophenyl phosphate
(Sigma Chemical Co) was added. Color changes were monitored by a Dynatech MicroELISA
Reader MR 7000 (Dynatech, Chantilly, VA) at 410 nm. Standard curves were established using
known concentrations of mouse IgG (Sigma Chemical Co.), and the concentrations of unknown
samples were extrapolated by using the BioLinx computer program (Dynatech, Chantilly, VA).
The means +/− SE of the relative concentrations of antibody from individual mice assayed in
duplicated are reported in micrograms per milliliter.
Assay for detection of antibody to the P815 Cells
P815 cells were plated into a 24 well plate and allowed to grow confluent for 3 days. Serum
from mice injected with PBS, P815 cells, or P815-MAA were incubated with the cells at a 1:50
dilution, and incubated at 4°C overnight. The plate was washed 3 times with Hanks Balanced
Salt Solution (HBSS) containing 2% BSA 100 µl of FITC Rb × Ms IgG antibody (Zymed
Laboratories, San Francisco, CA) was added and the plate incubated for 45 minutes at 4°C.
The plate was washed 3 times with HBSS and fluorescent binding to the cells evaluated using
a Flourolite spectrophotometer (Dynatech, Chantilly, VA). The values are expressed as relative
fluorescence following subtraction from the secondary antibody. As a positive control, to
determine assay function, a FITC Rb × Ms Class I H2kd antibody (BD Biosciences, San Jose,
CA) was incubated with the P815 cells as these cells constitutively express MHC Class I.
IL-12 Production by Peritoneal Macrophages
DBA/2 mice immunized with PBS, P815 cells, or P815-MAA were injected with one milliliter
of 3% Brewer’s thioglycollate medium intra peritoneal (33). Mice were killed 7 days later by
cervical dislocation, 10 ml of DMEM-10 was injected intra peritoneal, and peritoneal fluid was
withdrawn and placed in sterile 15 ml siliconized tubes (Becton Dickinson Vacutainer System,
Franklin Lakes, NJ). Cells were placed in 24 well culture plates and exposed to 25 µg/ml of
Alb or MAA-Alb at 37°C for 2, 4, 6, and 24 hours. A commercially available mouse IL-12
cytokine kit form (BD Biosciences, San Jose, CA) was used to look for IL-12 production in
the supernatant.
Lethal P815 Dose
In order to determine the minimum concentration of viable P815 cells that resulted in 100%
mortality in DBA/2 mice, a dose response assay was done. P815 cells were first passaged
through the peritoneal cavity of a DBA/2 mouse. The mouse was watched for the presence of
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ascites. After a week of incubation the cells were removed, counted, and normal DBA/2 mice
were injected via the tail vein with various doses of the viable (non-irradiated) P815 cells. Mice
were watched daily and the time of death recorded. A survival curve was used to determine
the proper dose with which to challenge immunized mice.
P815 Challenge after MAA Injections
After 6 weeks of PBS, P815, or P815-MAA injections the mice were challenged with a lethal
dose via the tail vein of P815 cells at a concentration of 1 × 105 cells. Mice were watched daily
and checked for survival. A survival curve was generated by plotting the number of days
following the injection with the tumor by the percent of mouse survival after the challenge.
Statistical analysis
Results were expressed as means +/− SEM. Statistical significance was achieved if P values
were less than 0.05. All statistical analysis was performed using the Students T-test in
SigmaStat (Jandel Scientific, 2002).
Results
Antibody to the MAA Epitope
To begin assessing the antibody response to the MAA epitope, sera from mice injected with
PBS, P815 or P815-MAA were screened for antibody to MAA or the carrier cell proteins. As
shown in Figure 1, PBS injected animals had background levels of antibody to the Alb or MAA-
Alb adduct (167 and 200 µg/ml respectively). These numbers increased (315 Alb and 508 µg/
ml MAA-Alb) when serum from P815 irradiated cells were screened on Alb or MAA-Alb.
However, P815-MAA injection increased the antibody to the MAA-Alb epitope 2 fold over
P815 irradiated cells (300 Alb and 1092 MAA-Alb µg/ml). Immunizations of 1mM AA-
modified or 1mM MDA-modified cells in the absence of adjuvant were looked and
demonstrated background levels of antibodies to the cells or the AA or MDA adduct (data not
shown). These data demonstrate that antibody to the MAA adduct is present in these animals.
Antibody to P815 Cells
To determine if P815-MAA injection induced antibodies against the P815 cells, a fluorescent
assay was developed as described in materials and methods. For these studies, serum from
mice immunized with PBS, P815 irradiated or P815-MAA irradiated cells were incubated with
P815 cells and detected by immunofluorescence. Figure 2 shows only modest increases in
antibody to P815 cells in serum from PBS or P815 irradiated and injected animals (120 and
99 relative fluorescent units respectfully). Serum from animals immunized with P815-MAA
irradiated cells showed an increased activity to the P815 cells 3–4 fold (371 relative fluorescent
units) as compared to the controls.
Peritoneal Macrophage IL-12 Production
To determine whether macrophage sensitization, by the MAA adduct occurs, peritoneal
macrophage were isolated from PBS, P815 irradiated or P815-MAA irradiated and immunized
animals, stimulated with Alb or MAA-Alb (in vitro), and assayed for IL-12 release. As shown
in Figure 3 animals immunized with PBS or P815 irradiated cells showed small amounts of
IL-12 production (20 and 35 ng/ml respectfully). P815-MAA injected animals increase IL-12
release 3 fold over the controls (142 ng/ml), and stimulation by Alb had only minimal effects
on the production of IL-12. These data demonstrate that macrophages from P815-MAA
injected mice are sensitized to the MAA adduct.
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Survival of DBA/2 mice after P815-MAA Injection
After 5 weeks of injection with PBS and P815 or P815-MAA irradiated cells, the mice were
injected via the tail vein with 105 lethal P815 cells. The mice were monitored and counted daily
for survival. As shown in Figure 4, 100% of the mice preimmunized with PBS survived only
14 days post tumor injection. Mice preimmunized with P815 irradiated cells after 14 days
showed only a 20% survival and at 18 days all had died. However, P815-MAA preimmunized
animal survival was increased by 4 days. Figure 5 demonstrates the tumor log kill of P815 cells
following a challenge with 105 P815 viable cells. These data show that after a lethal dose of
P815 cells the PBS preimmunized animals had a mean survival of 14.25 days and the immune
system only killed 102 tumor cells prior to death. Mice preimmunized with P815 irradiated
cells had a mean survival of 15.75 days and approximately 104 tumor cells were killed prior
to death. DBA/2 mice that were preimmunized with P815-MAA had a mean survival of 18.25
days and the immune system eradicated 105 tumor cells prior to death. These data demonstrate
that P815-MAA immunized animals survive longer and are capable of clearing a larger number
of tumor cells prior to death of the animal.
Discussion
It has been suggested that immune components are associated with the development and/or
progression of ALD. Previous studies performed by our laboratory have demonstrated that
Malondialdehyde-Acetaldehyde (MAA) modified proteins are formed under physiological
conditions (16) and are immunogenic in the absence of adjuvant (30). However, the cellular
mechanism(s) by which tissue damage is accomplished is unclear. In an effort to begin
examining these cellular mechanisms, which are most likely initiated during the killing of
hepatocytes modified with MAA (34,35), experiments were designed using the P815 model
of tumor rejection. Therefore, it was the purpose of these experiments to determine if MAA-
modified P815 tumor cells could be used as a model system for examining the cytotoxicity of
hepatocytes that has been observed in ALD.
P815 cells modified with MAA and injected into DBA/2 mice, generated serum antibody titers
to the MAA epitope that was 2 fold higher over mice injected with only irradiated cells. These
experiments demonstrated that antibody against MAA epitopes were produced in these
animals. Importantly, it was also possible to show that antibody to P815 cells was present in
the mouse sera, and was increased 4 fold in serum from P815-MAA immunized mice as
compared to sera from P815 or the PBS immunized control mice. Thus, the antibody response
was not only to the adduct, but to the cellular material. Should antibody be involved through
complement activation or antibody dependent cellular cytotoxicity, then the response to the
cell and not just the adduct would lend greater specificity to the tissue damage.
The cytokine IL-12 has long been known to play a role in both the innate and adaptive immune
response to tumor cells by inducing macrophages, CD8+ T cells, and secondary cytokines that
destroy tumor cells (36,37). Previous studies performed by our laboratory have shown that
MAA-adducted proteins bind to scavenger receptors on peritoneal macrophages, sinusoidal
liver endothelial cells, and Kupffer cells (29,38,39). It was also shown that macrophages could
release pro-inflammatory cytokines in response to MAA-modified proteins (39). In this present
study peritoneal macrophages were isolated from DBA/2 mice that had been immunized with
PBS, P815 irradiated cells or P815-MAA adducted and irradiated cells. The cells were then
incubated with Alb or MAA-Alb and the supernatant was assayed for the release of IL-12, and
showed there was a 3 fold increase in IL-12 production over the Alb control. It is tempting to
speculate that a Th1 type of immune response has been elicited to activate macrophages and
Th1 cytokine responses.
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The ability of these mice to generate antibody to both the MAA adduct and macromolecules
on the P815 cells, in conjunction with the production of IL-12 by peritoneal macrophages,
provides a possible mechanism by which immune responses to cells of the liver (hepatocytes)
may be initiated in ALD. For these studies P815 cells modified with MAA were injected into
DBA/2 mice as described, and a lethal dose of P815 cells was intravenously injected. Mice
injected with PBS or P815 irradiated cells only, lived for 14 and 15 days respectfully after
infusion of lethal doses of P815 cells. However, mice immunized with P815 MAA modified
cells and infused with P815 cells lived for 18 days, increasing their survival by 3 to 4 days.
When mean log tumor kill was assessed, P815-MAA injected animals killed more tumor cells
than either the PBS or P815 irradiated cells. These data strongly suggest that an immune
response to the tumor cell proteins was generated in response to the MAA-modified P815 cells.
If these were MAA modified liver cells, then the target organ would be the liver, and cell death
could occur in a similar fashion as the P815 cells.
Data generated from these studies show that modification of tumor cells with malondialdehyde
and acetaldehyde (MAA) causes significant immune responses in the absence of adjuvant.
These MAA adducts have already been detected in both human (16) and rat livers (40)
chronically consuming ethanol. It has been suggested that if these adducts are formed during
chronic inflammation (alcohol and oxidative stress) and modify cells of the liver, harmful
results may occur. If these modified self proteins from the liver are processed by dendritic cells
with the right co-stimulatory molecules (B7-1/B7-2) (41), it may be possible to generate T
helper, T-cytotoxic, and antibody to the self proteins, potentially initiating damage to the liver
cells similar to that observed using the P815 model used in this study. Importantly, this may
serve as a model system to investigate NK and T-cytotoxic cell death in the context of ALD
due to the metabolites of chronic ethanol consumption.
In summary, when DBA/2 mice are immunized with P815 MAA-modified cell lysates, an
immune response to both the P815 cells and the MAA epitope are observed. Peritoneal
macrophages from these animals are pre-sensitized to MAA and release IL-12 in response to
MAA stimulations. When DBA/2 mice, pre-immunized with P815 MAA modified cells are
challenged with lethal tumor cells, an increased tumor kill in vivo is observed, which serves as
a model of tissue specific cellular cytotoxicity. More work is needed to be performed to find
the underlying mechanisms by which MAA induces these responses.
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Antibody activity to the MAA epitope in DBA/2 mice immunized with PBS, P815 or P815-
MAA modified cells as assayed on Alb or MAA-Alb. Serum from DBA/2 mice injected with
P815-MAA modified cells contained a 2 fold increase in MAA antibody when compared to
the DBA/2 mice injected with P815 cells. Mice injected with PBS had only background
antibody production to Alb or MAA-Alb. Each bar is the mean SE of 5 mice. * P< 0.05,
significantly different from PBS and P815 injected animals when sera was screened on MAA-
Alb. # P < 0.05 significantly different from PBS and P815 injected animals when screened on
Alb.
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Antibody activity to P815 cells in DBA/2 mice immunized with PBS, P815 or P815-MAA
modified cells. Serum from DBA/2 mice was incubated with P815 cells and the antibody
activity determined. Mice injected with P815-MAA had a 3 fold increase in antibody activity
to the P815 cells, while the mice injected with P815 cells or PBS had background levels of
approximately 100 relative fluorescent units. Each bar is the mean SE of 5 mice. * P < 0.001,
significantly different from PBS and P815 injected animals.
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IL-12 release by peritoneal macrophages presensitized with P815-MAA cells. Peritoneal
macrophage from DBA/2 mice injected with PBS, P815 or P815-MAA modified cells were
incubated in the presence of (25 µg/ml) Alb or MAA-Alb for 3 hours. Supernatant was assayed
for IL-12 production. P815-MAA injected animals showed a 3 fold increase in IL-12 over the
PBS or P815 injected animals. Each bar is the mean SE of 5 mice. * P < 0.001, significantly
different from PBS and P815 injected animals when MAA-Alb was used as the antigen. # P <
0.001 significantly different from PBS or P815 injected animals when Alb was used as the
antigen.
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Survival of mice immunized with PBS, P815 or P815-MAA cells modified following the
administration of a lethal dose of P815 cells. Mice immunized with PBS lived 14 days, while
P815 injected animals lived 14–18 days. However, mice immunized with P815-MAA modified
cells lived 4 days longer than the PBS of P815 injected animals. Each point is the mean SE of
6 mice.
Duryee et al. Page 13














Survival of DBA/2 mice challenged with P815 cells. Data were extrapolated and expressed to
show the concentration of cells needed to kill mice. Briefly, mice immunized with PBS and
P815 cells require 102 and 104 cells respectfully in order to induce tumor and death. However,
mice pre-immunized with P815-MAA cells required 105 cells to induce tumor and death. Each
point is the mean SE of 6 mice.
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